2025 (1 POST)
Monticello TM , MacLachlan TK, Funk KA, Rock BM, Bussiere JL, Grieves JL, Schuh JCL, Henry S. 2025. Nonclinical safety assessment: An overview of drug and medical device development. Chapter 1 in: Bouchard PR, Sahota PS, Wallace S, Wojcinski ZW, Schumacher VL (eds), Toxicologic Pathology: Nonclinical Safety Assessment, 3rd edition. Boca Raton: CRC Press-Taylor and Francis Group, pp. 3-51.
Topics: drug development , medical devices , nonclinical safety assessment
2024 (2 POSTS)
Monticello TM , Potter DM, Huang Q, Hart TK, Shuey D, Troth S, Vergis JM, Tassew N, et al. 2024. Do longer duration nonclinical toxicology studies provide predictive clinical safety value? The IQ Consortium longer duration nonclinical to clinical translational database. Toxicol Appl Pharmacol 492(Sept 5):117087; doi: 10.1016/j.taap.2024.117087 .
View Abstract
Topics: animal testing , nonclinical safety assessment , Toxicology
Bienvenu JG, Chouinard L, Felix M, Boyce, RW, Monticello TM . 2024. Inhibition of both sclerostin and DKK1 results in novel skull findings in the rat and non-human primate that is not observed with inhibition of sclerostin alone. Bone 179(Feb):116985; doi: 10.1016/j.bone.2023.116985 .
View Abstract
Topics: sclerostin
2022 (1 POST)
Coppi A, Davies R, Wegesser T, Ishida K, Karmel J, Han J, Aiello F, Xie Y…, Monticello TM , et al. 2022. Characterization of false positive, contaminant- driven mutagenicity in impurities associated with the sotorasib drug substance. Regul Toxicol Pharmacol 131(June):105162; doi: 10.1016/j.yrtph.2022.105162 .
View Abstract
Topics: drug development , sotorasib
2021 (2 POSTS)
Werner JA, Davies R, Wahlstrom J, Dahal UP, Jiang M, Stauber J, David B, Siska W…, Monticello TM . 2021. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12C, are associated with renal toxicity in the Sprague Dawley rat. Toxicol Appl Pharmacol 423(July 15):11578; doi: 10.1016/taap.2021.115578 .
Topics: sotorasib
Ishida K, Werner J, Lafleur N, Wisler J, Wannberg S, Kalanzi J, Bussiere J, Monticello TM . 2021. Phosphatidylinositol 3-kinase δ-specific inhibitor-induced changes in the ovary and testis in the Sprague Dawley rat and cynomolgus monkey. Int J Toxicol 40(4):344-354; doi: 10.1177/109158211008175 .
View Abstract
Topics: phosphatidylinositol 3 kinase
2020 (1 POST)
Bogdanfy MS, Lesnick J, Mangipudy R, Sistare FD, Colman K, Garcia-Tapla D, Monticello T , Blanset D. 2020. Tg.rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals: Industry survey of current practices. Int J Toxicol 39(3):198-206; doi: 10.1177/1091581820919896 .
View Abstract
Topics: carcinogens , pharmaceuticals
2019 (2 POSTS)
Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM, Chellman GJ, Balasubramanian G, Monticello TM . 2019. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol 106(Aug):224-238; doi: 10.1016/j.yrtph.2019.05.013 .
View Abstract
Topics: migraines , nonclinical safety assessment , Toxicology
Prior H, Monticello T , Boulifard V, Brennan FR, Kimber I. 2019. Integration of consortia recommendations for justification of animal use within current and future drug development paradigms. Int J Toxicol 38(4):319-325; doi: 10.1177/1091581819852922 .
View Abstract
Topics: drug development , safety assessment
2018 (1 POST)
Monticello TM , Bussiere JL. 2018. Nonclinical safety evaluation of drugs. Chapter 2 in: Sahota PS, Popp JA, Hardisty JF, Gopinath C. (eds), Toxicologic Pathology: Nonclinical Safety Assessment, 2nd edition. Boca Raton: CRC Press-Taylor and Francis Group, pp. 27-64.
Topics: drug development , nonclinical safety assessment
2017 (1 POST)
Monticello TM , Jones TW, Dambach DM, Potter DM, Bolt MW, Liu M, Keller DA, Hart TK, et al. 2017. Current nonclinical testing paradigm enables safe entry to First-in-Human clinical trials: The IQ consortium nonclinical translational database. Toxicol Appl Pharmacol 334(Nov 1):100-109; doi: 10.1016/j.taap.2017.09.006 .
View Abstract
Topics: nonclinical safety assessment
2015 (1 POST)
Monticello TM . 2015. Drug development and nonclinical to clinical translational databases: Past and current efforts. Toxicol Pathol 43(1):57-61; doi: 10.1177/0192623314557189 .
View Abstract
Topics: databases , drug development
2012 (1 POST)
Monticello TM , Bussiere JL. 2012. Nonclinical safety evaluation of drugs. Chapter 2 in: Sahota PS, Popp JA, Hardisty JF, Gopinath C. (eds), Toxicologic Pathology: Nonclinical Safety Assessment. Boca Raton: CRC Press-Taylor and Francis Group, pp. 25-54.
Topics: drug development , nonclinical safety assessment
2007 (1 POST)
Wang X, Hsu M-Y, Steinbacher TE, Monticello TM , Schumacher WA. 2007. Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction. Thromb Res 119(5):595-600; doi: 10.1016/j.thromres.2006.04.011 .
View Abstract
Topics: PCR
2006 (1 POST)
Rose WC, Marathe PH, Jang G, Monticello TM , Balasubramanian BN, Long B, Fairchild C, Wall ME, Wani MC. 2006. Novel fluoro-substituted campthothecins: In vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer Chemother Pharmacol 58(1):73-85; doi: 10.1007/s00280-005-0128-y .
View Abstract
Topics: drug development , pharmacokinetics , Toxicology
1999 (1 POST)
Trippodo NC, Fox M, Monticello TM , Panchal BC, Asaad MM. 1999. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34(6):782-790; doi: 10.1097/00005344-199912000-00003 .
View Abstract
Topics: vasopeptidase inhibitors
1997 (2 POSTS)
Bolton L, Zaki G, Monte K, Durham SK, Monticello TM , Hudak J, Shannon R, Wilfinger W, et al. 1997. Tissue repair in space. Wounds 9(4):127-142.
Topics: Tissue repair
Aversa CA, Oparil S, Caro J, Li H, Sun S, Chen YF, Swerde MR, Monticello TM , et al. 1997. Hypoxia stimulates human preproendothelin-1 (PPET-1) promoter activity in transgenic mice. Am J Physiol 273(4):L848-L855; doi: 10.1152/ajplung.1997.273.4.L848 .
View Abstract
Topics: hypoxia
1996 (3 POSTS)
Grover GJ, Dzwonczyk S, Monticello TM . 1996. Comparative cardioprotective effects of cromakalin and diltiazem in ischemic hypertrophied and non-hypertrophied rat hearts. Am J Physiol 270(1 Pt 2):H174-H182; doi: 10.1152/ajpheart.1996.270.1.H174 .
View Abstract
Topics: cardiac hypertrophy
Monticello TM , Swenberg JA, Gross EA, Leininger JR, Kimbell JS, Seilkop S, Starr TS, Gibson JE, et al. 1996. Correlation of regional and nonlinear formaldehyde-induced nasal cancer with proliferating populations of cells. Cancer Res 56(5):1012-1022 .
View Abstract